Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-dose Administration of Botulinum Toxin
High-dose Jeuveau, with a dosage double that of the existing 20 units, has succeeded in Phase 2 clinical trials as Extra StrengthDemonstrating a proven long-term efficacy of 6 months or 26 weeks, Jeuveau enhances global product competitiveness by
Source: newswit.com